Pfizer Inc. (PFE)
28.45
-0.36
(-1.25%)
USD |
NYSE |
Sep 04, 16:00
28.42
-0.03
(-0.11%)
After-Hours: 20:00
Pfizer Research and Development Expense (TTM) : 10.82B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.82B |
| March 31, 2026 | 10.52B |
| December 31, 2025 | 10.25B |
| September 30, 2025 | 10.13B |
| June 30, 2025 | 10.20B |
| March 31, 2025 | 10.44B |
| December 31, 2024 | 10.74B |
| September 30, 2024 | 10.49B |
| June 30, 2024 | 10.61B |
| March 31, 2024 | 10.56B |
| December 31, 2023 | 10.58B |
| September 30, 2023 | 11.42B |
| June 30, 2023 | 11.43B |
| March 31, 2023 | 11.62B |
| December 31, 2022 | 11.43B |
| September 30, 2022 | 13.73B |
| June 30, 2022 | 13.71B |
| March 31, 2022 | 13.14B |
| December 31, 2021 | 12.83B |
| September 30, 2021 | 10.27B |
| June 30, 2021 | 9.884B |
| March 31, 2021 | 9.72B |
| December 31, 2020 | 9.403B |
| September 30, 2020 | 8.865B |
| June 30, 2020 | 8.846B |
| Date | Value |
|---|---|
| March 31, 2020 | 8.602B |
| December 31, 2019 | 8.621B |
| September 30, 2019 | 8.247B |
| June 30, 2019 | 7.966B |
| March 31, 2019 | 7.925B |
| December 31, 2018 | 7.966B |
| September 30, 2018 | 7.83B |
| June 30, 2018 | 7.681B |
| March 31, 2018 | 7.667B |
| December 31, 2017 | 7.631B |
| September 30, 2017 | 7.829B |
| June 30, 2017 | 7.851B |
| March 31, 2017 | 7.817B |
| December 31, 2016 | 7.837B |
| September 30, 2016 | 7.68B |
| June 30, 2016 | 7.527B |
| March 31, 2016 | 7.515B |
| December 31, 2015 | 7.67B |
| September 30, 2015 | 8.521B |
| June 30, 2015 | 8.591B |
| March 31, 2015 | 8.575B |
| December 31, 2014 | 8.311B |
| September 30, 2014 | 6.903B |
| June 30, 2014 | 6.74B |
| March 31, 2014 | 6.546B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Johnson & Johnson | 15.06B |
| Eli Lilly & Co. | 14.60B |
| Merck & Co., Inc. | 27.26B |
| Bristol Myers Squibb Co. | 9.548B |
| Viatris, Inc. | 995.00M |